GSK plc (FRA:GS70)
Germany · Delayed Price · Currency is EUR | Market Cap | 90.65B +18.5% |
| Revenue (ttm) | 38.56B +5.0% |
| Net Income | 5.60B +40.8% |
| EPS | 2.81 +42.6% |
| Shares Out | n/a |
| PE Ratio | 15.99 |
| Forward PE | 10.19 |
| Dividend | 1.53 (3.53%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | n/a |
| Open | 44.60 |
| Previous Close | 43.40 |
| Day's Range | 44.60 - 45.00 |
| 52-Week Range | 36.80 - 52.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK presents updated data from phase I BEHOLD-1 trial for Mo-Rez
GSK (GSK) announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, Mo-Rez, an investigational B7-H4-targeted antibody-drug conjugate, ADC. Results showed clinically mean...
GSK announces interim results from phase II AZUR-1 trial of Jemperli
GSK (GSK) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instabilit...
Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties
Ionis Pharmaceuticals, Inc. reported that its partner, GSK, announced that the U.S. Food and Drug Administration has approved HIBSAGO for the treatment of chronic hepatitis B virus infection in combin...
GSK’s ViiV announce real-world evidence from OPERA cohort using Cabenuva
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced evidence from the OPERA observational cohort spanning five years of real-world...
Ionis Pharmaceuticals partner GSK announces FDA approval of Hibsago
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced that the FDA has approved Hibsago for the treatment of chronic hepatitis B, or CHB, virus infection in combination with nucleoside analogue rev...
FDA Approves GSK's Hibsago For Chronic Hepatitis B In Adults Without Cirrhosis
(RTTNews) - GSK plc (GSK) announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) to treat chronic hepatitis B (CHB) virus infection in combination with nucleos(t)...
GSK (GSK) Gains FDA Approval for Hibsago, Enhancing Dividend Appeal
GSK (GSK) Gains FDA Approval for Hibsago, Enhancing Dividend Appeal
GSK’s Hibsago approved by FDA for treatment of CHB
GSK (GSK) “announced that the FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B, CHB, virus infection in combination with nucleos(t)ide analogue reverse transcriptase in...
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB)...
FDA Approves GSK's Hibsago, Boosting Prospects for Dividend Sustainability (GSK)
FDA Approves GSK's Hibsago, Boosting Prospects for Dividend Sustainability (GSK)
FDA Approves GSK's Hibsago Injection for Chronic Hepatitis B, Boosting Dividend Stock Appeal (GSK)
FDA Approves GSK's Hibsago Injection for Chronic Hepatitis B, Boosting Dividend Stock Appeal (GSK)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
GSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer
(RTTNews) - GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch rep...
GSK announces FDA approval of Jemperli
GSK (GSK) announced the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high/mismatch repair deficient locally advanced r...
GSK (GSK) Gains FDA Approval for Jemperli, Boosting Outlook for Dividend Investors
GSK (GSK) Gains FDA Approval for Jemperli, Boosting Outlook for Dividend Investors
AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion for Jemperli
AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion for Jemperli
AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer
AnaptysBio (ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK (GSK) company, and Quimilza with Vanda, announced that GSK has received U.S. Food and…
GSK confirms FDA approval of Jemperli for certain rectal cancers
GSK (GSK) announced the Food and Drug Administration has approved Jemperli as “the first and only immunotherapy” for adults with stage II and III microsatellite instability-high/mismatch repair defici...
GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Monday the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate (ADC), in pati...
GSK (GSK) Reports Promising Phase Ib Data for Risvutatug Rezetecan in Small Cell Lung Cancer
GSK (GSK) Reports Promising Phase Ib Data for Risvutatug Rezetecan in Small Cell Lung Cancer
GSK announces global data for risvutatug rezetecan
GSK (GSK) announced the first global data for risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate, in patients with relapsed extensive-stage small cell lung cancer, ES-SCL...
Belgian Minister To Closely Monitor GSK Restructuring Plan
(RTTNews) - On October 14, The Belgian government has pledged to closely monitor the restructuring plans announced by GSK plc. (GSK), with David Clarinval, Belgium's Deputy Prime Minister and Minister...
GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Investors
GSK PLC (GSK) Shares Surge 3.5% -- What GF Score of 77 Tells Investors
GSK Plans Major Restructuring in Belgium, Impacting Over 1,200 Jobs (Ticker: GSK)
GSK Plans Major Restructuring in Belgium, Impacting Over 1,200 Jobs (Ticker: GSK)
GSK (GSK) Plans Workforce Reduction in Belgium Amid Restructuring Efforts
GSK (GSK) Plans Workforce Reduction in Belgium Amid Restructuring Efforts